Jing Li
Primary Care · San Antonio, TXNPI 1760811020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,967, more than ten times the $60 reported in 2021. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novartis$1K
- Johnson & Johnson$824
- UCB, Inc.$500
- Mallinckrodt Hospital Products Inc.$442
- Pfizer$319
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,22099%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 80 | $1,251 |
| Novartis | 53 | $1,076 |
| Johnson & Johnson(2 entities) | 43 | $824 |
| UCB, Inc. | 22 | $500 |
| Mallinckrodt Hospital Products Inc. | 18 | $442 |
| Pfizer | 21 | $319 |
| Lilly USA, LLC | 17 | $295 |
| E.r. Squibb & Sons, L.L.C. | 15 | $291 |
| Radius Health, Inc. | 11 | $206 |
| ANI Pharmaceuticals, Inc. | 9 | $199 |
| Aurinia Pharma U.S., Inc. | 6 | $141 |
| Fresenius Kabi USA, LLC | 6 | $128 |
| Boehringer Ingelheim | 5 | $104 |
| AstraZeneca | 4 | $74 |
| GSK | 4 | $60 |
| Genentech USA, Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Sandoz | 2 | $36 |
| Invivyd Inc | 2 | $33 |
| Bayer | 1 | $30 |
| Sobi, Inc | 1 | $30 |
| Almatica Pharma LLC | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| AbbVie | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
How this compares
$6,301 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 23 | $114,930 |
| Enbrel SureclickEtanercept | 14 | $106,281 |
| Humira(Cf)Adalimumab | 15 | $99,907 |
| Hydroxychloroquine Sulfate | 124 | $3,189 |
| Lidocaine | 13 | $3,152 |
| Doxycycline Hyclate | 81 | $2,451 |
| MethotrexateMethotrexate Sodium | 133 | $2,246 |
| Leflunomide | 38 | $1,844 |
| Methylprednisolone | 76 | $971 |
| Pregabalin | 50 | $678 |
| Sulfasalazine | 35 | $661 |
| Leucovorin Calcium | 14 | $596 |
| Tramadol Hcl | 66 | $521 |
| Prednisone | 50 | $504 |
| Duloxetine Hcl | 14 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,251 | $114,93023 claims |
| AbbVieHumira(Cf) | $16 | $99,90715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in San Antonio
- Phillip GulleySan Antonio$23K
- Charlotte BallardSan Antonio$9K
- Christopher LoganSan Antonio$8K
- Lydia Chapa WilsonSan Antonio$7K
- Lauryn SaenzSan Antonio$5K
- Brittany CurrySan Antonio$4K
- Martha RuizSan Antonio$3K
- Ryan WenclSan Antonio$3K
- Gabriella MutschlechnerSan Antonio$3K
- Mary GibbensHouston$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.